Gram-negative aerobic bacteria account for 10%-17% of periprosthetic joint infection (PJI). Due to its biofilm-activity, ciprofloxacin plays a key role in the treatment of gram-negative PJI. However, data about treatment outcome of these infections are conflicting. With this retrospective study we aim at evaluating characteristics and outcome of gram-negative PJI. We retrospectively included consecutive patients with gram-negative PJI treated at our institution from 01/2013 to 03/2018. Diagnosis of PJI was defined by the proposed European Bone and Joint Infection Society (EBJIS) criteria. Growth of gram-negative aerobic bacteria was required in synovial fluid, periprosthetic tissue or sonication fluid. Clinical success (infection-free status) was defined as fulfillment of all of the following criteria: (i) unremarkable surgical site and no subsequent surgery (ii) no PJI related mortality and (iii) no long-term antimicrobial suppression therapy of >6 months.Aim
Method